VCYT VERACYTE, INC.
Services-Medical Laboratories · Nasdaq · SEC CIK 1384101 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.5%
TTM net income YoY318.4%
TTM EPS YoY305.3%
Revenue 3-yr CAGR19.2%
Net income 3-yr CAGR—
Margins
Gross margin72.0%
Operating margin17.1%
Net margin21.8%
FCF margin27.8%
EBITDA margin20.8%
Returns
ROE9.4%
ROA8.6%
ROIC (approx.)9.1%
Asset turnover0.40x
Leverage & solvency
Liabilities / assets8.9%
Debt / equity0.00x
Current ratio5.56x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.37x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $517.14M | $445.76M |
| Gross profit | $362.53M | $298.14M |
| R&D expense | $70.81M | $69.29M |
| SG&A expense | $110.78M | $110.61M |
| Operating income | $57.78M | $16.14M |
| Pretax income | $68.20M | $25.74M |
| Income tax | $1.85M | $1.61M |
| Net income | $66.35M | $24.14M |
| EBITDA | $79.19M | $39.60M |
| EPS (basic) | 0.84 | 0.32 |
| EPS (diluted) | 0.82 | 0.31 |
| Weighted avg. shares (diluted) | 80.57M | 78.16M |
| Balance sheet | ||
| Cash & equivalents | $362.58M | $240.63M |
| Short-term investments | $50.31M | — |
| Receivables | $44.66M | $46.52M |
| Inventory | $20.55M | $21.75M |
| Current assets | $488.38M | $372.27M |
| PP&E, net | $22.19M | $22.95M |
| Goodwill | $767.15M | $745.80M |
| Intangibles | $89.15M | $102.30M |
| Total assets | $1.41B | $1.30B |
| Current liabilities | $59.94M | $78.63M |
| Total liabilities | $96.44M | $124.07M |
| Shareholders' equity | $1.31B | $1.18B |
| Shares outstanding | 79.36M | 77.77M |
| Cash flow statement | ||
| Operating cash flow | $136.31M | $75.10M |
| Capital expenditure | $9.68M | $11.29M |
| Free cash flow | $126.63M | $63.81M |
| Investing cash flow | -$9.21M | -$56.27M |
| Financing cash flow | -$4.22M | $4.90M |
| Depreciation & amortization | $21.41M | $23.46M |
| Stock-based compensation | $43.60M | $36.25M |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.